Susan Ramus

Professor of Molecular Oncology

University of New South Wales

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Susan Ramus is a faculty member at the University of New South Wales, Australia. Her research focuses on molecular oncology, particularly in the field of ovarian cancer, including studies on tumor hormone receptor expression, genetic susceptibility, and the tumor microenvironment. She has contributed to significant findings in ovarian cancer risk, management of aggressive tumors, and implications of genomic analyses on treatment outcomes.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Collaborators (28)

Weiva Sieh

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Susan Ramus

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.

Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology.

Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes.

Cellular origins of mucinous ovarian carcinoma

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.

Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.

Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma

Co-observation of germline pathogenic variants in breast cancer predisposition genes

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.

Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies

Collaborators (28)

Weiva Sieh

William Newman

Marco Montagna

Graham Mann

Jacques Simard

Britton Trabert

Anthony Howell

Maria Jose Garcia

Martin Köbel

Pei-Chen Peng

ATOCHA ROMERO

Dennis Hazelett

Diana M Eccles

Hui Shen

Denise G. O'Mahony

Taru Muranen

Michael Anglesio

Anna Gonzalez-Neira

Stig E. Bojesen

Cheng-Han Lee

Manuel António Rodrigues Teixeira

Dale Garsed

Hoda Anton-Culver

Paul Pharoah

Håkan Olsson

Felix Grassmann

Natalia Bogdanova

Paul Cohen

Make your next move.